LONDON–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/Technavio?src=hash” target=”_blank”gt;#Technaviolt;/agt;–The global non-small cell lung cancer drugs market is expected to post a
CAGR of more than 13% during the period 2019-2023, according to the
latest market research report by Technavio.
Over the years, the prevalence of non-small cell lung cancer has been
increasing at a rapid pace, resulting in a high unmet need for
disease-modifying drugs. As a result, several companies have been
focusing on R&D for the development of new drugs, which has resulted in
the development of a strong drug pipeline for the treatment of non-small
lung cancer. A number of drugs have been approved, and several others
are in the final stages of approval. Thus, recent drug approvals will
drive market growth during the forecast period.
As per Technavio, the use of predictive biomarkers for the development
of cost-effective therapies will have a positive impact on the market
and contribute to its growth significantly over the forecast period.
non-small cell lung cancer drugs market 2019-2023 research
report also analyzes other important trends and market drivers that will
affect market growth over 2019-2023.
Global non-small cell lung cancer drugs market:
Use of predictive biomarkers for the development of cost-effective
Lung cancer is a highly heterogeneous disease that can develop either
due to gene expression patterns or genetic mutations, which can result
in uncontrolled cellular growth and progression. Therefore, the use of
biomarkers is highly significant which helps in determining the
mutational status of genes. Most of non-small cell lung cancer treatment
guidelines recommend the need for biomarker testing as part of the
routine diagnosis, prior to initiating therapy in the first-line
setting. The use of predictive biomarkers that provide information about
the effect of a therapeutic intrusion has become crucial as it helps in
the development of cost-effective therapies with improved clinical
“The prevalence of non-small cell lung cancer has increased
significantly across the world owing to the rise in risk factors such as
cigarette smoking, secondary smoking, air pollution, and occupational
exposure. Lung cancer is the leading cause of cancer deaths worldwide.
The rapid industrial development and urbanization are also the major
factors driving the high prevalence of lung cancer. This will increase
the need for new and effective drugs that can treat non-small cell lung
cancer,” says a senior research analyst at Technavio.
Global non-small cell lung cancer drugs market:
This market research report segments the global non-small cell lung
cancer drugs market by products (biologics, small molecule targeted
therapy, and chemotherapy) and geographic regions (Asia, Europe, North
America, and ROW).
The biologics segment held the largest non-small cell lung cancer drugs
market share in 2018. The growth of the biologics segment can be
attributed to the availability of biologics that are used in
immunotherapy, the increasing adoption of biologics, recent drug
launches, and the strong pipeline targeting first-line treatments for
patients with non-small cell lung cancer.
The North America region led the market in 2018, followed by Europe,
Asia, and ROW respectively. The market in North America is driven by
factors such as the access to patient assistance and co-pay relief
programs, the high prevalence of non-small cell lung cancer, strong
pipeline and new drug approvals in the region.
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
Five Forces Analysis
- Regional comparison
- Key leading countries
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
Media & Marketing Executive
+1 844 364 1100
UK: +44 203 893 3200